We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+5.69%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$1.11B
AUM Growth
-$139M
Cap. Flow
-$141M
Cap. Flow %
-12.73%
Top 10 Hldgs %
67.11%
Holding
44
New
8
Increased
11
Reduced
15
Closed
10

Top Buys

Rank Stock Value
1
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$36M
2
CYTK icon
Cytokinetics
CYTK
+$24.1M
3
TBIO
Translate Bio, Inc. Common Stock
TBIO
+$14.5M
4
CCXI
ChemoCentryx, Inc.
CCXI
+$13.6M
5
XENT
Intersect ENT, Inc
XENT
+$13.5M

Top Sells

Rank Stock Value
1
AKBA icon
Akebia Therapeutics
AKBA
+$47.7M
2
TGTX icon
TG Therapeutics
TGTX
+$39.6M
3
ZYME icon
Zymeworks
ZYME
+$34.6M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$26.6M
5
NXTC icon
NextCure
NXTC
+$21.4M

Sector Composition

Rank Sector Weight
1 Healthcare 95.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IOVA icon
1
Iovance Biotherapeutics
IOVA
$1.82B
$128M 11.48%
3,876,600
+151,624
+4% +$4.65M
SAGE
2
DELISTED
Sage Therapeutics
SAGE
$120M 10.81%
1,966,688
-135,680
-6% -$6.88M
ACAD icon
3
Acadia Pharmaceuticals
ACAD
$4.43B
$79.3M 7.13%
1,921,563
+116,570
+6% +$5.03M
ARNA
4
DELISTED
Arena Pharmaceuticals Inc
ARNA
$74.6M 6.71%
996,898
-305,501
-23% -$20.4M
ZYME icon
5
Zymeworks
ZYME
$1.61B
$73M 6.57%
1,567,900
-1,006,788
-39% -$34.6M
UTHR icon
6
United Therapeutics
UTHR
$25.8B
$64.7M 5.82%
640,773
+20,773
+3% +$2.28M
CNST
7
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$58M 5.22%
2,861,924
-618,076
-18% -$15.1M
CYTK icon
8
Cytokinetics
CYTK
$10.5B
$55.2M 4.97%
2,549,525
+1,028,890
+68% +$24.1M
GWPH
9
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$50.6M 4.56%
520,232
+70,232
+16% +$8.08M
TGTX icon
10
TG Therapeutics
TGTX
$7.96B
$42.8M 3.85%
1,600,000
-1,720,808
-52% -$39.6M
MGNX icon
11
MacroGenics
MGNX
$235M
$38M 3.42%
1,510,215
+10,215
+0.7% +$279K
AUPH icon
12
Aurinia Pharmaceuticals
AUPH
$1.91B
$36.6M 3.29%
+2,485,327
New +$36M
GBT
13
DELISTED
Global Blood Therapeutics, Inc.
GBT
$36.2M 3.25%
655,676
+113,476
+21% +$7.21M
BHVN
14
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$28.3M 2.54%
435,000
-405,900
-48% -$26.6M
VCEL icon
15
Vericel Corp
VCEL
$2.35B
$27.4M 2.47%
1,480,787
-129,367
-8% -$2.14M
GKOS icon
16
Glaukos
GKOS
$9.83B
$22.1M 1.99%
446,097
-53,903
-11% -$2.37M
GERN icon
17
Geron
GERN
$828M
$16.9M 1.52%
9,685,528
-5,712,551
-37% -$10.6M
PRTA icon
18
Prothena Corp
PRTA
$425M
$15.5M 1.39%
1,548,479
-534,362
-26% -$6.43M
SGMO
19
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$15M 1.35%
1,589,724
+9,833
+0.6% +$106K
CCXI
20
DELISTED
ChemoCentryx, Inc.
CCXI
$13.9M 1.25%
+253,230
New +$13.6M
TBIO
21
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$12.8M 1.16%
+943,339
New +$14.5M
ALLO icon
22
Allogene Therapeutics
ALLO
$649M
$12.4M 1.12%
+328,817
New +$12.4M
XENT
23
DELISTED
Intersect ENT, Inc
XENT
$12.2M 1.1%
+747,926
New +$13.5M
IVA
24
Inventiva
IVA
$1.06B
$11.8M 1.06%
+999,422
New +$11.5M
PBYI icon
25
Puma Biotechnology
PBYI
$404M
$11.1M 1%
1,102,073
+1,009,571
+1,091% +$10.3M
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q3 2020 Portfolio in Review

As of Q3 2020, Great Point Partners held 44 positions worth $1.11B, down 11% from $1.25B the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Great Point Partners withdrew a net $141M in Q3 2020, closing 10 positions and reducing 15 holdings. Its most notable exit was Akebia Therapeutics, an estimated $47.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 98% a quarter earlier.

Against the trend, Great Point Partners opened a new position in Aurinia Pharmaceuticals worth $36.6M.

  • Great Point Partners's largest Q3 2020 buy was Aurinia Pharmaceuticals: 2,485,327 shares worth $36.6M.
  • Great Point Partners added most to Cytokinetics in Q3 2020, an estimated $24.1M increase.
  • Great Point Partners's biggest Q3 2020 reduction was TG Therapeutics, cutting an estimated $39.6M.
  • Great Point Partners fully exited Akebia Therapeutics in Q3 2020, selling an estimated $47.7M.
  • Great Point Partners's ten largest holdings make up 67% of its $1.11B portfolio in Q3 2020.
  • Great Point Partners opened 8 new positions and closed 10 in Q3 2020.
  • Great Point Partners's portfolio value fell 11% quarter-over-quarter to $1.11B.

Based on Great Point Partners's 13F filing for Q3 2020, filed 16 Nov 2020.